Gilead Sciences, Inc.
Head Quarters
333 Lakeside Drive USWebsite
http://www.gilead.comIndustry
BiotechnologyEmployees
9000Exchange
NASDAQGilead Sciences, Inc. is a biopharmaceutical company, which discovers, develops and commercializes therapeutics for unmet medical need. It focuses on human immunodeficiency virus and liver diseases, such as chronic hepatitis C virus infection & chronic hepatitis B virus infection, hematology & oncology, and cardiovascular & inflammation as well as respiratory diseases. The company's products include Descovy, Odefsey, Genvoya, Stribild, Complera, Atripla, Truvada, Viread, Emtriva, Tybost, Vitekta, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, Hepsera, Zydelig, Letairis, Ranexa, Lexiscan, Cayston, Tamiflu, AmBisome and Macugen. Gilead Sciences was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Key statistics
Margins | Stock |
---|---|
Revenue per Employee | $0.00 |
Current Ratio | 2 |
Gross Margin (%) | 0.86% |
Net Margin (%) | 0.09% |
Returns | Stock |
Sales | $29.07B |
Sales Growth (% qtr vs. yr ago) | 0.00% |
Net Income | $2.93B |
NI Growth (% qtr vs. yr ago) | 0.00% |
Price/Sales | 13.63 |
EPS | $9.00 |